BioPharmSignal logoBioPharmSignal

Biotech News

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Aziyo Biologics (AZYO)Aziyo BiologicsConference / presentation

GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief

Related news

AZYOAziyo Biologics2026-09-02 20:05 EST

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

AZYOAziyo Biologics2026-01-09 13:00 EST

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery

View all latest news

Aziyo Biologics

Drug-Eluting Biomatrix Company Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site. Antibiotic-Eluting Platform The company's biomatrix technology incorporates antibiotics into a biologic scaffold. The platform was first...

Recent company news

AZYOAziyo Biologics2026-09-10 20:05 EST

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

AZYOAziyo Biologics2026-09-02 20:05 EST

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

AZYOAziyo Biologics2026-08-18 12:00 EST

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

AZYOAziyo Biologics2026-08-13 20:10 EST

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

AZYOAziyo Biologics2026-08-13 20:05 EST

Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States